The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.

The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.

Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.

Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.

The present invention provides polypeptides and their variants and derivatives which modulate GABA.sub.A receptor function at nanomolar quantities by binding to the α+/β− subunit interface, as well as methods of making and using the same. The inventive peptides are useful for the study of neurological disease and function and can have therapeutic applications.

A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX.sub.1CNLPVKPGPCX.sub.2GFFSAFYYSQKX.sub.3NKCHSFTYGGCAGNANRFSTX.sub.4EKCRRTC X.sub.5X.sub.6, wherein, X.sub.1 is the amino acid residue F or G, X.sub.2 is any amino acid residue, except a basic amino acid residue, X.sub.3 is the amino acid residue T or D, X.sub.4 is the amino acid residue I, L, or E, (i) X.sub.5 is V and X.sub.6 is G or (ii) X.sub.5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.

A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX.sub.1CNLPVKPGPCX.sub.2GFFSAFYYSQKX.sub.3NKCHSFTYGGCAGNANRFSTX.sub.4EKCRRTC X.sub.5X.sub.6, wherein, X.sub.1 is the amino acid residue F or G, X.sub.2 is any amino acid residue, except a basic amino acid residue, X.sub.3 is the amino acid residue T or D, X.sub.4 is the amino acid residue I, L, or E, (i) X.sub.5 is V and X.sub.6 is G or (ii) X.sub.5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.

Novel peptides and their uses are provided. In particular, the peptides are useful for increasing glucose uptake or decreasing hepatic glucose production. The peptides are also useful for regulating glucose levels and/or treating diabetes in a subject.

The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.

The present invention refers to the heterologous production in microorganisms of modified versions of a predicted isoform of the surfactant protein Lv-ranaspumin-1 (Lv-Rsn-1), whose sequence was inferred from analyzes of the protein extract of the nest foam from the Northeastern Pepper Frog (Leptodactylus vastus). More specifically, it refers to two surfactant proteins that consist of modified versions of the predicted isoform of Lv-Rsn-1; to two synthetic genes each encoding one of these modified versions of the predicted isoform of Lv-Rsn-1; to two expression cassettes each containing one of the synthetic genes encoding one of the modified versions of the predicted isoform of Lv-Rsn-1; to two expression vectors each containing one of the synthetic genes encoding modified versions of the predicted isoform of Lv-Rsn-1; and to two transgenic microorganisms, a bacterium and a yeast, each transformed with one of these synthetic genes and heterologously producing one of the modified versions of the predicted isoform of Lv-Rsn-1. Lv-Rsn-1 has surfactancy, emulsification and dispersancy properties, among others, and its heterologous production allows it to be used in various applications and industrial products, without the need to extract it from the frog nest foam.